Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN)

Representative David Taylor (Republican-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on October 1st, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on September 22nd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 9/22/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/22/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 9/8/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 9/8/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.

Amgen Stock Performance

Amgen stock opened at $403.04 on Friday. The business has a 50 day moving average of $410.72 and a 200-day moving average of $370.33. The company has a market capitalization of $217.90 billion, a P/E ratio of 25.05, a P/E/G ratio of 2.94 and a beta of 0.41. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the firm posted $6.02 EPS. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.5%. Amgen’s dividend payout ratio is currently 62.65%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Amgen

A number of institutional investors and hedge funds have recently modified their holdings of the business. Baird Financial Group Inc. increased its holdings in Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after acquiring an additional 5,496 shares during the last quarter. MW Advisory LLC purchased a new stake in Amgen during the second quarter valued at about $1,054,000. Integrated Advisors Network LLC grew its position in shares of Amgen by 50.5% in the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after purchasing an additional 6,356 shares in the last quarter. KBC Group NV lifted its holdings in Amgen by 51.7% during the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after purchasing an additional 130,497 shares in the last quarter. Finally, Nilsine Partners LLC bought a new position in Amgen in the 2nd quarter worth about $3,329,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Bank of America boosted their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Citigroup upped their price target on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. TD Cowen increased their price target on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Piper Sandler lifted their price objective on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, UBS Group reiterated a “buy” rating and issued a $430.00 target price on shares of Amgen in a report on Thursday, September 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $385.25.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.